Bristol-Myers Squibb (BMY) DIvidends Date & History

Key Takeaways

• Attractive yield: Bristol-Myers Squibb (BMY) pays an annualized dividend of $2.52 per share, or $0.63 per quarter, for a yield of roughly 4%.
• Consistent payer: The company has raised its dividend for 17 consecutive years and has a history of uninterrupted payments spanning decades.
• Moderate growth, not rapid: Recent increases have been small — the latest raise was about 1.6% — as management conserves cash ahead of patent expirations.
• Covered by cash flow: Free cash flow covers the dividend several times over, providing a cushion despite a higher earnings-based payout ratio in some periods.
• Above-average for the sector: BMY's yield is well above the healthcare industry median of roughly 2.3%, positioning it as an income-oriented holding.

Dividend Overview

Bristol-Myers Squibb is a global biopharmaceutical company best known for oncology, cardiovascular, and immunology therapies. Its dividend profile places it firmly among income-focused large-cap pharmaceutical names rather than a pure dividend-growth story. The company pays a quarterly dividend of $0.63 per share, equivalent to an annualized $2.52 per share and a dividend yield of approximately 4% at recent prices.

Payments are made every three months, with the most recent ex-dividend date of October 2, 2026, and a payment date of November 2, 2026. The yield is meaningfully higher than the broader S&P 500 average and the healthcare industry median, reflecting both the company's steady cash generation and a share price that has lagged the broader market in recent years. BMY is best described as a modest-growth, higher-yield dividend stock rather than a high-octane dividend grower.

Dividend History and Growth

Bristol-Myers Squibb has a long and dependable record of returning cash to shareholders. The company has increased its dividend for 17 consecutive years, and its payout has been paid without interruption for well over nine decades — a rare sign of durability across economic and patent cycles.

The pace of growth, however, has slowed in recent years. The quarterly payout stepped up from $0.57 in 2023 to $0.60 in 2024, $0.62 in 2025, and $0.63 in 2026. Over the past five years, the dividend has grown at an annualized rate of roughly 1.6%, while the 10-year average increase is closer to 5%. The most recent increase of about 1.6% signals that management is deliberately preserving cash as key products approach loss of exclusivity. This pattern of smaller, steady raises reflects a conservative capital-allocation strategy rather than an aggressive dividend-growth mandate.

Dividend Sustainability and Payout Ratio

The dividend appears reasonably well covered, although the picture differs depending on the metric used. Based on trailing earnings, the payout ratio is approximately 55%, while estimates for the current and next fiscal year suggest a ratio in the high-30% range. On a cash-flow basis, the payout is even more comfortable, with dividends consuming roughly 30% to 40% of free cash flow (the cash a company generates after capital spending).

In fiscal 2025, Bristol-Myers Squibb generated about $12.9 billion in free cash flow against roughly $5 billion in dividend payments — coverage of roughly 2.5 times. This cash cushion is important because reported net income swings sharply with acquisition-related and impairment charges. The main watch item is the balance sheet: net debt sits near $33 billion, and upcoming patent expirations for blockbuster products could pressure future cash flow. Management's choice to slow dividend growth suggests it is prioritizing financial flexibility, which generally supports the payout's durability.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, BMY's yield stands out. The healthcare industry median dividend yield is approximately 2.3%, making BMY's roughly 4% yield notably higher than the sector norm. Compared with large-cap peers, BMY sits between the lower-yielding growth names and the highest-yielding income plays: companies such as Eli Lilly (LLY) and Merck (MRK) offer lower yields, while Pfizer (PFE) yields above BMY at roughly 6%. Johnson & Johnson (JNJ) and AbbVie (ABBV) fall closer to or slightly below BMY's level.

This positioning means BMY offers an above-average income stream relative to its industry, but its yield also reflects investor concerns about patent expirations and a heavy debt load. For dividend investors, the comparison frames BMY as a higher-income, slower-growth alternative within the pharmaceutical group.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For income-focused investors, the screener can help identify dividend stocks, breakout candidates, and trending opportunities far more efficiently than manual screening. Explore the AI Screener to streamline your research and uncover ideas aligned with your strategy.

Is This Stock Attractive for Dividend Investors?

BMY is most likely to appeal to income-oriented and conservative investors who prioritize a steady, above-market cash yield over rapid payout growth. The combination of a roughly 4% yield, 17 consecutive years of increases, and strong free-cash-flow coverage makes it a candidate for those seeking recurring income with a measure of durability.

That said, the stock is less suited to investors who require aggressive dividend growth. The modest recent increases and the looming patent expirations for key products introduce uncertainty around future cash flows and, by extension, future payout growth. The elevated net debt also warrants attention. For long-term dividend investors willing to tolerate slower growth and sector-specific risks, BMY's yield and payment history are notable positives. However, the sustainability of the dividend will depend on management successfully navigating the coming loss of exclusivity period. Investors should weigh the attractive current income against these forward-looking risks before forming a view.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations